EPISODE · May 5, 2021 · 30 MIN
49. IRPL Technology with I-MED Pharma: Part One
from Four Eyes · host Modern Optometry
This episode is sponsored by I-MED PHARMA. I-MED Pharma is a Canadian company specializing in dry eye diagnosis and management since 1989. I-MED Pharma provides innovative ocular surface disease solutions to Canadian optometrists, ophthalmologists, and the global eye care community. The company has a wide variety of dry eye disease products including preservative-free artificial tears, eye masks, omega supplements, lid scrubs, and the E>EYE IRPL device. In the first episode of this two-part discussion, we talk with I-MED Pharma brand representative Blair about the research and technology behind the E>EYE IRPL device, how it benefits dry eye patients with meibomian gland dysfunction, and how it compares to IPL. Visit https://imedpharma.com/irpl/ to learn more about the E>EYE IRPL device. Be sure to follow @imedpharma on Instagram to keep up with their latest innovative products!
What this episode covers
This episode is sponsored by I-MED PHARMA. I-MED Pharma is a Canadian company specializing in dry eye diagnosis and management since 1989. I-MED Pharma provides innovative ocular surface disease solutions to Canadian optometrists, ophthalmologists, and the global eye care community. The company has a wide variety of dry eye disease products including preservative-free artificial tears, eye masks, omega supplements, lid scrubs, and the E>EYE IRPL device. In the first episode of this two-part discussion, we talk with I-MED Pharma brand representative Blair about the research and technology behind the E>EYE IRPL device, how it benefits dry eye patients with meibomian gland dysfunction, and how it compares to IPL. Visit https://imedpharma.com/irpl/ to learn more about the E>EYE IRPL device. Be sure to follow @imedpharma on Instagram to keep up with their latest innovative products!
NOW PLAYING
49. IRPL Technology with I-MED Pharma: Part One
No transcript for this episode yet
Similar Episodes
Nov 7, 2023 ·5m
Nov 7, 2023 ·5m
Nov 5, 2023 ·11m
Nov 5, 2023 ·10m
Nov 5, 2023 ·9m
Nov 5, 2023 ·9m